CD274 and neoplasm: Taken collectively, a large meta-analysis of 43 studies and 5431 patients who underwent neoadjuvant chemoimmunotherapy demonstrated that even in patients with tumor PD-L1 < 1%, there was a significant improvement in event-free survival (but not OS) compared with chemotherapy alone [180].